Biomea Fusion, Inc.

Healthcare · Biotechnology · United States

Last price 0.6228 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 45.14M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ...